


































tandem	 mass	 spectrometry	 (LC‐MS/MS)	 method	 was	 developed	 for	 simultaneous






and	 255.75	 →	 166.15	 (m/z)	 for	 tamsulosin,	 finasteride	 and	 diphenhydramine	 (IS),
respectively,	on	a	triple	quadrupole	mass	spectrometer.	The	linearity	was	obtained	over
the	 concentration	 range	 of	 1.6‐40.0	 ng/mL	 for	 tamsulosin	 and	 20.0‐500.0	 ng/mL	 for
finasteride	with	a	lower	limit	of	detection	of	0.5	ng/mL	and	5.0	ng/mL	for	the	two	drugs,
respectively.	 The	 proposed	 method	 was	 successfully	 applied	 to	 tamsulosin	 and
finasteride	 determination	 in	 pharmaceutical	 dosage	 form.	 The	 results	 obtained	 were
statistically	 analyzed	 and	 compared	 with	 those	 of	 reference	 ones;	 in	 addition,	 the












Tamsulosin	 (TAM)	 is	 a	 sulfamoylphenethylamine	
derivative	 (Figure	 1)	 commonly	 used	 to	 treat	 signs	 and	
symptoms	of	benign	prostatic	hyperplasia	(BPH)	[1,2].	TAM	is	a	
selective,	 potent	 and	 competitive	 α1‐adrenoceptor	 antagonist	
[3,4].	 The	USP	has	described	a	potentiometric	method	 for	 the	
analysis	of	TAM	[5],	besides;	various	analytical	techniques	have	
been	reported	 for	 the	determination	of	TAM	 in	bulk,	pharma‐
ceutical	formulations	and	biological	samples.	These	techniques	
include	 HPLC	 [6‐9],	 stability	 indicating	 HPLC	 [10],	 stability	
indicating	HPTLC	[11],	LC‐MS/MS	[12‐14],	potentiometry	[15],	
voltametry	 [16],	 capillary	 electrophoresis	 [17],	 spectrofluori‐
metry	[18],	UV	[19]	and	visible	spectrophotometry	[20].	
Finasteride	 (FIN),	N‐(1,1‐dimethylethyl)‐3‐oxo‐(5α,17β)‐4‐
azaandrost‐1‐ene‐17‐carboxamide	 (Figure	 1),	 is	 a	 synthetic	
antiandrogen	which	acts	by	inhibiting	type	II	5‐α	reductase,	the	




daily	 [21].	 In	 addition	 to	 the	 HPLC	 method	 described	 by	 the	
USP	 [5],	 several	 methods	 for	 determination	 of	 FIN	 in	 bulk,	
pharmaceutical	formulations	and	biological	samples	have	been	
developed.	 These	 methods	 include	 HPLC	 [22],	 polarography	
[23]	and	LC‐MS	[24,25].	
There	are	 few	published	methods	 for	 the	high	 throughput	
determination	 of	 TAM	 and	 FIN	 in	 bulk	 and	 combined	 dosage	
forms	 previously	 reported	 using	 HPLC	 and	 TLC	 methods	
[26,27].	
The	 lack	 of	 LC‐MS/MS	 methods	 for	 the	 simultaneous	
analysis	 of	 both	 TAM	 and	 FIN	 has	motivated	 us	 to	 develop	 a	
simple,	 sensitive	 and	 validated	 LC‐MS/MS	 method	 for	 their	
determination.	 For	 best	 detection	 up	 to	 nano‐gram	 level	 of	
TAM	 and	 FIN;	 the	 chromatographic	 conditions	 and	 the	 mass	
spectrometric	 parameters	 were	 thoroughly	 studied	 and	
adjusted.	The	method	was	subsequently	used	to	determine	the	
concentration	of	the	drugs	in	 laboratory	prepared	mixtures	as	
well	 as	 in	 combined	 dosage	 forms.	 Our	 experimental	 results	
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(IS)	 were	 purchased	 from	 Sigma	 Pharmaceutical	 Industries,	
Steinheim,	Germany.	Their	purities	were	certified	and	analyzed	
by	 reference	methods	and	were	 found	 to	be	 99.54%	 for	TAM	
[26]	 and	 99.86%	 for	 FIN	 [5].	 They	 were	 used	 as	 provided.	
Urimax	 F	 tablets	 (0.4	 mg	 TAM	 +	 5	 mg	 FIN)	 Cipla	
Pharmaceutical	Ltd.,	Mumbai,	 India.	All	solvents	and	materials	
were	 of	 HPLC	 grade.	 Methanol	 was	 purchased	 from	 Fischer	
Scientific	 UK	 Ltd,	 Loughborough,	UK.	 Acetonitrile	 and	






MAX	 triple	 stage	 quadrupole	 mass	 spectrometer,	
Thermoscientific,	 New	 York,	 USA,	 equipped	 with	 an	
electrospray	ionization	(ESI)	source.	Xcalibur	software	version	
2.2	 was	 used	 to	 control	 the	 LC‐MS/MS	 system,	 collect	 and	
analyse	 the	 data.	 The	 HPLC	 system	 consisted	 of	 an	 Accela	 U‐





The	 positive‐ion	 mass	 spectrometric	 detection	 method	
utilised	electrospray	ionization	and	single	reaction	monitoring	





Chromatographic	 separation	 was	 performed	 on	 Hypersil‐










Stock	 solutions	 (0.1	 mg/mL)	 of	 TAM,	 FIN	 and	 IS	 were	










Six	 standard	 solutions	 of	 each	 drug	 were	 prepared	 in	
concentration	 ranges	1.6‐40.0	ng/mL	 for	TAM	and	20.0‐500.0	
ng/mL	 for	 FIN	with	 the	 addition	 of	 40	 ng/mL	 of	 IS	 on	 every	
standard	solution.	A	10	μL	aliquot	of	each	solution	was	injected	









then	 40.0	 ng/mL	 of	 IS	 was	 added.	 A	 10	 μL	 aliquot	 of	 each	






were	 pulverized	 well;	 an	 accurate	 amount	 of	 the	 powdered	
Mohamed	et	al.	/	European	Journal	of	Chemistry	5	(1)	(2014)	181‐185	 183	
 
tablets	 equivalent	 to	 12.5	mg	 of	 FIN	 and	 1.0	mg	 of	 TAM,	was	
weighed	 and	 transferred	 into	 100	 mL	 volumetric	 flask	 and	







conditions	 and	 the	mass	 spectrometric	 parameters.	 Precursor	
ions	and	product	 ions	were	optimized	by	infusing	1.00	µg/mL	
neat	solutions	into	mass	spectrometer	in	about	a	100‐500	m/z	
range,	 in	 positive	 polarity	mode	 using	 electrospray	 ionization	
technique.	 Best	 intensity	 for	 precursor	 ions	 and	 product	 ions	
was	found	in	the	positive	mode	for	both	drugs	as	they	have	the	
ability	 to	accept	protons.	The	protonated	molecular	 ions	 [M	+	
H]+	of	TAM,	FIN	and	IS,	observed	on	the	full	scan	mass	spectra,	
were	408.74,	373.11	and	255.75	m/z,	respectively.	
Moreover,	 the	 collision	 energy	 in	Q2	 produced	 significant	
fragments.	 The	MS/MS	 transition	408.74	→	227.29,	 373.11	→	
304.96	and	255.75	→	166.15	for	TAM,	FIN	and	IS,	respectively,	
were	selected	since	 these	products	 ions	 represented	 the	most	















To	 obtain	 the	 best	 chromatographic	 separation	 with	 the	
desired	response	it	was	observed	that,	mobile	phase	as	well	as	
selection	of	column	is	an	important	criterion.	Chromatographic	
analysis	 of	 the	 drugs	 and	 IS	 was	 initiated	 under	 isocratic	
conditions	with	the	aim	to	develop	a	simple	separation	process	
with	 a	 short	 run	 time.	 Separation	 was	 tried	 using	 various	
combination	 of	 acetonitrile	 and	 buffer	 solution	 with	 varying	
contents	of	each	component	on	different	columns	like	Hypersil‐





ammonium	 acetate	 buffer	 pH	 adjusted	 to	 3.5	 with	 acetic	
acid:acetonitrile	 (10:90,	 v:v)	 was	 found	 suitable	 as	 the	 drugs	




















ng/mL	 for	 FIN.	 The	 linearity	 of	 standard	 curves	 (r2)	 for	 all	
analytes	 were	 greater	 than	 0.99.	 The	 calibration	 curve	 had	 a	















Parameter	 Tamsulosin	 Finasteride 
Linearity	range	 1.60	‐ 40.00	ng/mL 20.00	‐ 500.00	ng/mL	















Item	 Tamsulosin	 Finasteride 
Proposed	 Reported	[26]	c Proposed Reported	[5]	d	
Mean	b	±	SD	 100.11±0.78	 99.54±0.88 100.01±0.61 99.86±0.81	
%	RSD	 0.78	 0.88 0.69 0.81	
%	REr	 0.32	 0.44 0.28 0.40	
n	 6	 4 6 4	
Variance	 0.61	 0.77 0.47 0.65	
t‐	test	(2.31)	 1.08	 0.32 	
F‐	test	(5.409)	 1.26	 	 1.37	 	
Intraday	precision	b	 99.83±0.77	 99.75±0.63 	












Tamsulosin	 Finasteride	 Tamsulosin	 Finasteride	
30.00	 30.00	 101.04 97.95	
30.00	 60.00	 100.45 98.06	
40.00	 20.00	 99.76	 99.95	
10.00	 125.00	 100.35	 99.55	
30.00	 375.00	 98.76 100.09	









Statistical	 analysis	 [28]	 obtained	 by	 the	 proposed	 and	
reported	methods	 using	 student´s	 t‐test	 and	 variance	 ratio	 F‐
test,	showed	no	significant	difference	between	the	performance	
of	 the	 two	 methods	 regarding	 the	 accuracy	 and	 precision,	
respectively,	(Table	3).		
In	 addition,	 the	 intraday	 precision	was	 evaluated	 through	
replicate	 analysis	 of	 the	 standard	 solutions	 of	 the	 drugs.	
However,	 the	 interday	 precision	 was	 performed	 through	
replicate	 analysis	 of	 the	 standard	 solutions	 of	 the	 drugs	 on	
three	successive	days.	The	percentage	recoveries	as	well	as	the	







The	 limit	 of	 quantification	 (LOQ)	 was	 determined	 by	
establishing	 the	 lowest	 concentration	 that	 can	 be	 measured	










by	 the	 consistency	 of	 the	 relative	 peak	 area	 values	 with	 the	
deliberately	minor	 changes	 in	 the	 chromatographic	 and	mass	






The	 proposed	 method	 was	 successfully	 applied	 to	 the	
analysis	 of	 TAM	 and	 FIN	 in	 laboratory	 prepared	 mixtures	
containing	both	drugs	 in	different	 ratios.	The	average	percent	
recoveries	 were	 based	 on	 the	 average	 of	 three	 replicate	
determinations	(Table	4). 
To	 indicate	 the	 potential	 of	 LC‐MS	 for	 quality	 control	 and	







Item	 Taken	concentration	(ng/mL)	 Added	concentration	(ng/mL)	 %	Recovery	b	
Tamsulosin	 Finasteride	 Tamsulosin Finasteride Tamsulosin	 Finasteride
5.00	 62.50	 5.00	 62.50	 99.95	 98.89	
5.00	 62.50	 10.00	 125.00	 99.99	 98.54	
5.00	 62.50	 15.00 187.50 98.16 98.24	
5.00	 62.50	 20.00 250.00 99.00 97.98	
5.00	 62.50	 25.00 312.50 98.85 99.69	
5.00																																	62.50	 30.00 375.00 98.05 97.00	
Mean	±	SD	 98.76±0.78	 98.12±0.89	 	 	 99.00±0.84	 98.39±0.90	
%	RSD	 0.79	 0.91	 0.85 0.92	
%	Rer	 0.32	 0.37	 0.35 0.37	






The	 concentrations	 of	 the	drugs	were	 calculated	 referring	
to	 the	 corresponding	 regression	 equation.	 The	 coupling	 of	 LC	
with	 MS/MS	 detection	 in	 the	 SRM	 mode	 showed	 high	
specificity,	because	only	 the	 ions	derived	 from	 the	analytes	of	
interest	 were	 monitored,	 thus,	 commonly	 used	 tablet	
excipients	did	not	 interfere	 in	 the	analysis	as	 indicated	by	the	





A	 rapid	 and	 precise	 liquid	 chromatography	 with	
electrospray	ionization	tandem	mass	spectrometry	method	for	
the	 determination	 of	 tamsulosin	 and	 finasteride	 in	 bulk	
powders	 and	 in	 pharmaceutical	 formulation	 was	 developed	
and	 validated.	 The	method	 offers	 several	 advantages	 such	 as	
unnecessary	 complete	 separation	 of	 analytes,	 non‐tedious	
sample	 preparation.	 In	 addition,	 the	 short	 run	 time	 and	 the	
relatively	low	flow	rate	allows	the	analysis	of	a	large	number	of	
samples	with	less	mobile	phase	that	proves	to	be	cost	effective.	
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